[Featured Stock] NKMax, US Subsidiary CTOS Receives Approval to Announce Autologous Cell Therapy Increase

[Asia Economy Reporter Lee Seon-ae] NKMax's stock price is on the rise.

As of 10 a.m. on the 21st, NKMax is trading at 23,600 KRW, up 12.65% from the previous day. During the session, it surged to 24,500 KRW.

This is interpreted as a result of the approval for NKGen Biotech, the U.S. subsidiary, to present the SNK01 monotherapy for refractory cancer at the 2021 Connective Tissue Oncology Society (CTOS) Annual Meeting.

NKMax is scheduled to present the Phase 1 clinical study of ‘SNK01’ at the CTOS Annual Meeting, which will be held online from November 10 to 13.

CTOS is a cancer society involving specialists and clinical experts related to connective tissue tumors, established in 1997 and held annually. Since last year, it has been conducted online due to COVID-19. The research title is “A Phase 1 Study of Dose Escalation of Ex Vivo Expanded Autologous Natural Killer Cells in Pathologically Confirmed Cancer Patients Refractory to Standard Therapies.”

Stephen Cha, Chief Medical Officer (CMO) of NKGen Biotech, said, "This result is the world’s first outcome in clinical trials of solid tumors using NK cells," adding, "The remarkable result of complete remission in malignant sarcoma is an important achievement in the development of NK cell therapy." He continued, "Currently, some patients continue to receive SNK01 and Bavencio, with one patient undergoing treatment for over 38 weeks."